Welcome to our dedicated page for Syros Pharmaceuticals news (Ticker: SYRS), a resource for investors and traders seeking the latest updates and insights on Syros Pharmaceuticals stock.
Syros Pharmaceuticals, Inc. (SYRS) is a pioneering life sciences company dedicated to transforming the treatment landscape for various diseases by strategically mapping gene regulatory circuits and modulating the factors that control gene expression. Syros stands out in the pharmaceutical industry for its groundbreaking gene control research and drug discovery capabilities, which integrate disease biology and genomic data in ways that are not commonly seen in traditional pharmaceutical R&D.
At the heart of Syros' innovative approach is a proprietary platform composed of advanced assay technologies, sophisticated bioinformatics, and deep biological insights. This platform, developed by Syros' seasoned senior leadership team, is designed to decode the complexities of gene regulation and uncover new therapeutic avenues.
While the scientific approach of Syros has broad applications across multiple therapeutic areas, the company has achieved notable success in oncology. Syros is working to address significant unmet medical needs, particularly in the treatment of hematologic malignancies, by developing new standards of care for frontline patient treatment.
Syros Pharmaceuticals is currently involved in several promising projects and partnerships aimed at advancing its clinical pipeline and expanding its impact on patient care. The company’s recent achievements and ongoing projects underscore its commitment to harnessing gene control research to develop innovative therapies.
Financially, Syros is strategically positioned to continue its research and development efforts, supported by robust funding and a clear vision for the future of precision medicine. With a focus on oncology, Syros continues to push the boundaries of what is possible in medical science, aiming to deliver groundbreaking treatments that can significantly improve patient outcomes.
Syros Pharmaceuticals (NASDAQ:SYRS) will host a live conference call and webcast on May 6, 2021, at 8:30 a.m. ET to discuss its first-quarter financial results and provide a corporate update. Investors can join the call by dialing 866-595-4538 domestically or 636-812-6496 internationally, using conference ID 5770919. The event will also be available via webcast on their website, with an archive accessible for 30 days post-event. Syros is focused on gene expression control and has a strong clinical pipeline, including SY-1425 for myelodysplastic syndrome and SY-2101 for acute promyelocytic leukemia.
Syros Pharmaceuticals (SYRS) reported financial results for Q4 and the full year 2020, achieving revenues of $5.7 million in Q4 and $15.1 million for the year. The net loss for Q4 was $30.1 million ($0.62 per share), compared to $19.7 million in Q4 2019. Cash and equivalents stood at $174 million as of December 31, 2020. The company announced significant advancements in its clinical programs, including initiating Phase 2 trials for SY-1425 in AML and SY-2101 in APL. Syros expects to continue funding its operations through 2023 with its current cash position.
Syros Pharmaceuticals (NASDAQ:SYRS) will host a live conference call and webcast on March 4, 2021, at 8:30 a.m. ET to discuss its fourth quarter and full year 2020 financial results. Investors can dial 866-595-4538 for domestic or 636-812-6496 for international access, using conference ID 4472467. A replay will be available for 30 days post-event. Syros is focused on developing treatments that modulate gene expression, with a clinical-stage pipeline that includes innovative therapies like SY-1425 for myelodysplastic syndrome and SY-5609 for solid tumors.
Syros Pharmaceuticals (NASDAQ:SYRS) announces participation in three investor conferences. The Cowen and Company 41st Annual Health Care Conference on March 1 will feature a panel titled Novel Oncology Targets at 1:20 p.m. ET. The 33rd Annual Roth Conference on March 15 will discuss Navigating Clinical Development in RARE Hematologic & Inflammatory Disease at 10:00 a.m. ET. Lastly, the Oppenheimer 31st Annual Healthcare Conference will occur on March 16, starting at 8:40 a.m. ET. Live webcasts will be available on the Syros website.
Syros Pharmaceuticals (NASDAQ: SYRS) has priced an underwritten public offering of 5,400,000 shares at $14.00 each, resulting in gross proceeds of approximately $75.6 million. Funds will support ongoing clinical and preclinical programs, along with general corporate purposes. The offering is expected to close on January 22, 2021, pending customary conditions. Underwriters have a 30-day option to purchase an additional 810,000 shares. The offering is made under a shelf registration effective from June 2020, with details available via the SEC.
Syros Pharmaceuticals (NASDAQ:SYRS) announced a public offering of common stock, aiming to generate funds for its clinical and preclinical programs, alongside general corporate purposes. The offering may include up to an additional 15% of shares through underwriter options. Joint book-running managers Cowen and Piper Sandler are overseeing the offering, which is subject to market conditions and regulatory approval. A preliminary prospectus will be filed with the SEC, detailing the terms of the offering. This initiative reflects Syros' commitment to advancing its innovative cancer treatments.
Syros Pharmaceuticals (NASDAQ:SYRS) is advancing towards becoming a commercial-stage company through strategic initiatives in targeted hematology and selective CDK inhibition. CEO Nancy Simonian highlighted plans to launch three clinical trials for higher-risk MDS, AML, and APL, aiming to set new care standards. Notably, Syros is on track to report Phase 1 trial data for SY-5609 in Q3 2021. The company ended 2020 with approximately $174 million in cash, believed sufficient to fund operations into H2 2022.
Syros Pharmaceuticals (NASDAQ:SYRS) will have its CEO, Nancy Simonian, M.D., present at the 39th Annual J.P. Morgan Healthcare Conference on January 7 at 2:50 p.m. ET. The presentation will be accessible via a live webcast on the Syros website, with an archived replay available for 30 days post-event. Syros is focused on developing medicines to control gene expression and has a clinical-stage pipeline, including innovative treatments for myelodysplastic syndrome, acute myeloid leukemia, and solid tumors. For more details, visit www.syros.com.
Syros Pharmaceuticals (NASDAQ:SYRS) announced the closure of a $90.5 million private financing deal with institutional investors, including Bain Capital Life Sciences. The financing included the sale of 10,312,500 shares of common stock and pre-funded warrants for an additional 1,000,000 shares, priced at $8.00 each. Proceeds will support Syros' clinical development pipeline and general corporate purposes. The securities are unregistered and will require a registration statement to be filed with the SEC within 30 days.
FAQ
What is the current stock price of Syros Pharmaceuticals (SYRS)?
What is the market cap of Syros Pharmaceuticals (SYRS)?
What does Syros Pharmaceuticals specialize in?
What is unique about Syros Pharmaceuticals' approach?
In which therapeutic areas has Syros Pharmaceuticals shown success?
What recent achievements has Syros Pharmaceuticals made?
What is the financial condition of Syros Pharmaceuticals?
What is the proprietary platform of Syros Pharmaceuticals?
How does Syros Pharmaceuticals impact patient treatment?
Where is Syros Pharmaceuticals making its mark in the pharmaceutical industry?
Who are the key contributors to Syros Pharmaceuticals' proprietary platform?
What is the mission of Syros Pharmaceuticals?
